Morphic Holding, Inc.

MORF

US61775R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-28 EDT			5-day change	1st Jan Change
30.78 ^USD	-0.08%		+4.36%	+6.56%

05-21	Morphic Demonstrates Novel Real-Time Visualization of Small Molecule A4ß7 Inhibition of Gut-Trafficking Cells	CI
04-25	Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

November 22, 2022 at 08:00 am

Morphic Therapeutic announced that the EMERALD-2 phase 2b study of MORF-057 in ulcerative colitis (UC) has commenced with the first patient receiving MORF-057.

Latest news about Morphic Holding, Inc.

Morphic Demonstrates Novel Real-Time Visualization of Small Molecule A4ß7 Inhibition of Gut-Trafficking Cells	05-21	CI
Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Morphic Holding Names Simon Cooper as Chief Medical Officer	03-19	MT
Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer	03-19	CI
Morphic Holding's Full Year 2023 Net Loss Widens, Collaboration Revenue Falls	02-22	MT
Morphic Holding, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
North American Morning Briefing : Stock Futures -2-	02-21	DJ
Transcript : Morphic Holding, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	01-10
Morphic Ethical Equities Fund Buys Back Shares	12-27	MT
Citigroup Starts Morphic Holding With Buy Rating, $46 Price Target	12-08	MT
RBC Cuts Price Target on Morphic Holding to $76 From $80, Keeps Outperform, Speculative Risk	11-06	MT
Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Morphic Holding, Inc. Announces Chief Executive Officer Changes	11-03	CI
Transcript : Morphic Holding, Inc. - Special Call	23-10-12
BMO Capital Lowers Price Target on Morphic to $52 From $106, Maintains Outperform Rating	23-09-28	MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence	23-09-26	CI
Morphic Chief Executive to Take Medical Leave of Absence; Shares Slump After Hours	23-09-26	MT
North American Morning Briefing : Yield Surge -2-	23-09-26	DJ
Morphic Holding's 37% Monday Slump Coincides With BTIG Analyst Downgrade, Stifel Share-Price Target Cut of Almost 50%	23-09-25	MT
Stifel Cuts Morphic Holding's Price Target to $33 From $61, Hold Rating Maintained	23-09-25	MT
BTIG Research Downgrades Morphic to Neutral From Buy	23-09-25	MT
Insider Sell: Morphic Holding	23-09-11	MT
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ
Stifel Downgrades Morphic Holding to Hold From Buy, Adjusts Price Target to $61 From $69	23-08-09	MT

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Companyâs Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Morphic Holding, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.78 USD

Average target price

56 USD

Spread / Average Target

+81.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHIC HOLDING, INC.	+6.56%	1.54B
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+37.57%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research

Morphic Holding, Inc.

Equities

MORF

US61775R1059

Biotechnology & Medical Research

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Latest news about Morphic Holding, Inc.

Chart Morphic Holding, Inc.

Company Profile

Income Statement Evolution

Ratings for Morphic Holding, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research